SECTION 1. SHORT TITLE.
    This Act may be cited as the ``National Clinical Care Commission 
Act''.
SEC. 2. NATIONAL CLINICAL CARE COMMISSION.
    (a) Establishment.--There is hereby established, within the 
Department of Health and Human Services, a National Clinical Care 
Commission (in this section referred to as the ``Commission'') to 
evaluate and make recommendations regarding improvements to the 
coordination and leveraging of programs within the Department and other 
Federal agencies related to awareness and clinical care for at least 
one, but not more than two, complex metabolic or autoimmune diseases 
resulting from issues related to insulin that represent a significant 
disease burden in the United States, which may include complications 
due to such diseases.
    (b) Membership.--
        (1) In general.--The Commission shall be composed of the 
    following voting members:
            (A) The heads of the following Federal agencies and 
        departments, or their designees:
                (i) The Centers for Medicare & Medicaid Services.
                (ii) The Agency for Healthcare Research and Quality.
                (iii) The Centers for Disease Control and Prevention.
                (iv) The Indian Health Service.
                (v) The Department of Veterans Affairs.
                (vi) The National Institutes of Health.
                (vii) The Food and Drug Administration.
                (viii) The Health Resources and Services 
            Administration.
                (ix) The Department of Defense.
                (x) The Department of Agriculture.
                (xi) The Office of Minority Health.
            (B) Twelve additional voting members appointed under 
        paragraph (2).
        (2) Additional members.--The Commission shall include 
    additional voting members, as may be appointed by the Secretary, 
    with expertise in the prevention, care, and epidemiology of any of 
    the diseases and complications described in subsection (a), 
    including one or more such members from each of the following 
    categories:
            (A) Physician specialties, including clinical 
        endocrinologists, that play a role in the prevention or 
        treatment of diseases and complications described in subsection 
        (a).
            (B) Primary care physicians.
            (C) Non-physician health care professionals.
            (D) Patient advocates.
            (E) National experts, including public health experts, in 
        the duties listed under subsection (c).
            (F) Health care providers furnishing services to a patient 
        population that consists of a high percentage (as specified by 
        the Secretary) of individuals who are enrolled in a State plan 
        under title XIX of the Social Security Act or who are not 
        covered under a health plan or health insurance coverage.
        (3) Chairperson.--The members of the Commission shall select a 
    chairperson from the members appointed under paragraph (2).
        (4) Meetings.--The Commission shall meet at least twice, and 
    not more than four times, a year.
        (5) Vacancies.--A vacancy on the Commission shall be filled in 
    the same manner as the original appointments.
    (c) Duties.--The Commission shall evaluate and make 
recommendations, as appropriate, to the Secretary of Health and Human 
Services and Congress regarding--
        (1) Federal programs of the Department of Health and Human 
    Services that focus on preventing and reducing the incidence of the 
    diseases and complications described in subsection (a);
        (2) current activities and gaps in Federal efforts to support 
    clinicians in providing integrated, high-quality care to 
    individuals with the diseases and complications described in 
    subsection (a);
        (3) the improvement in, and improved coordination of, Federal 
    education and awareness activities related to the prevention and 
    treatment of the diseases and complications described in subsection 
    (a), which may include the utilization of new and existing 
    technologies;
        (4) methods for outreach and dissemination of education and 
    awareness materials that--
            (A) address the diseases and complications described in 
        subsection (a);
            (B) are funded by the Federal Government; and
            (C) are intended for health care professionals and the 
        public; and
        (5) whether there are opportunities for consolidation of 
    inappropriately overlapping or duplicative Federal programs related 
    to the diseases and complications described in subsection (a).
    (d) Operating Plan.--Not later than 90 days after its first 
meeting, the Commission shall submit to the Secretary of Health and 
Human Services and the Congress an operating plan for carrying out the 
activities of the Commission as described in subsection (c). Such 
operating plan may include--
        (1) a list of specific activities that the Commission plans to 
    conduct for purposes of carrying out the duties described in each 
    of the paragraphs in subsection (c);
        (2) a plan for completing the activities;
        (3) a list of members of the Commission and other individuals 
    who are not members of the Commission who will need to be involved 
    to conduct such activities;
        (4) an explanation of Federal agency involvement and 
    coordination needed to conduct such activities;
        (5) a budget for conducting such activities; and
        (6) other information that the Commission deems appropriate.
    (e) Final Report.--By not later than 3 years after the date of the 
Commission's first meeting, the Commission shall submit to the 
Secretary of Health and Human Services and the Congress a final report 
containing all of the findings and recommendations required by this 
section.
    (f) Sunset.--The Commission shall terminate 60 days after 
submitting its final report, but not later than the end of fiscal year 
2021.

                               Speaker of the House of Representatives.

                            Vice President of the United States and    
                                               President of the Senate.
(This measure has not been amended since it was passed by the Senate on September 6, 2017.  National Clinical Care Commission Act (Sec. 2) This bill establishes within the Department of Health and Human Services (HHS) a National Clinical Care Commission to evaluate and make recommendations regarding improvements to the coordination and leveraging of federal programs related to complex metabolic or autoimmune diseases that result from issues related to insulin and represent a significant disease burden (e.g., diabetes). The commission must report on: (1) HHS programs that focus on prevention, (2) current activities and gaps in federal efforts to support clinicians in providing integrated care, (3) improvement in federal education and awareness activities related to prevention and treatment, (4) methods for outreach and dissemination of education and awareness materials, and (5) opportunities for consolidation of overlapping federal programs. The commission must submit an operating plan to HHS and Congress within 90 days of its first meeting. The commission is terminated after it submits a final report, but not later than the end of FY2021.
National Clinical Care Commission Act